Tolerability of Grazax-R in Children

This study has been completed.

Sponsored by:	ALK-Abelló A/S
Information provided by:	ALK-Abelló A/S
ClinicalTrials.gov Identifier:	NCT00298701

Purpose

This trial is performed to assess whether the Grazax-R treatment is safe to use in children aged 5-12 years.

Condition	Intervention	Phase
Allergy	Biological: ALK Grass tablet	Phase I

MedlinePlus related topics: Allergy

Study Type:	Interventional
Study Design:	Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety Study
Official Title:	A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Phase I Trial Investigating the Safety of GRAZAX-R in Children Aged 5-12 Years With Grass Pollen Induced Rhinoconjunctivitis (With/Without Asthma)

Further study details as provided by ALK-Abelló A/S:

Primary Outcome Measures:

Estimated Enrollment:	50
Study Start Date:	February 2006
Estimated Study Completion Date:	April 2006

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00298701

Locations

Sponsors and Collaborators

ALK-Abelló A/S

Investigators

Study Director:

Kim Simonsen, MD

ALK-Abelló A/S

More Information

Study ID Numbers:	GT-11
Study First Received:	March 1, 2006
Last Updated:	May 3, 2006
ClinicalTrials.gov Identifier:	NCT00298701
Health Authority:	Germany: Paul-Ehrlich-Institut

Keywords provided by ALK-Abelló A/S:

Allergy

Study placed in the following topic categories:

Hypersensitivity
Asthma

ClinicalTrials.gov processed this record on January 16, 2009